Psyadon Pharmaceuticals, Inc. Announces The Opening Of A New Clinical Trial Of Ecopipam For The Treatment Of Tourette’s Syndrome In Children Ages 7-17

GERMANTOWN, Md.--(BUSINESS WIRE)--Psyadon Pharmaceuticals, Inc. announced today the opening of the first four centers in a new Phase 2b clinical trial of ecopipam for the treatment of Tourette’s Syndrome in children ages 7 to 17. “We are excited to start this double-blind, placebo-controlled trial in children with Tourette’s Syndrome,” said Dr. Richard Chipkin, President and CEO of Psyadon. “The previous positive results from our open label study in adults with Tourette’s have encouraged us to move into this younger population where treatments with new mechanisms are desperately needed.”

Help employers find you! Check out all the jobs and post your resume.